1352546-75-8 Usage
Uses
Used in Sunscreen and Cosmetic Products:
1-Thia-6-aza-spiro[3.3]heptane-1,1-dioxide is used as a photo-protective agent in sunscreen and cosmetic products for its ability to absorb ultraviolet radiation, thereby protecting the skin from harmful sun damage.
Used in Pharmaceutical Products:
1-Thia-6-aza-spiro[3.3]heptane-1,1-dioxide is used as an active ingredient in pharmaceutical products due to its anti-inflammatory and antibacterial properties, which contribute to the treatment of conditions such as acne and rosacea.
Used in Personal Care Products:
1-Thia-6-aza-spiro[3.3]heptane-1,1-dioxide is used as a versatile ingredient in personal care products, leveraging its protective, anti-inflammatory, and antibacterial properties to enhance the efficacy and safety of these products.
Check Digit Verification of cas no
The CAS Registry Mumber 1352546-75-8 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,5,2,5,4 and 6 respectively; the second part has 2 digits, 7 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1352546-75:
(9*1)+(8*3)+(7*5)+(6*2)+(5*5)+(4*4)+(3*6)+(2*7)+(1*5)=158
158 % 10 = 8
So 1352546-75-8 is a valid CAS Registry Number.
1352546-75-8Relevant academic research and scientific papers
SUBSTITUTED BICYCLIC AZA-HETEROCYCLES AND ANALOGUES AS SIRTUIN MODULATORS
-
Page/Page column 177; 178, (2013/05/09)
Provided herein are novel substituted bicyclic aza-heterocycle sirtuin- modulating compounds and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.
